Prostate Cancer - Results from #720

Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study. August 8, 2024

Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients. August 8, 2024

Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. August 8, 2024

Harnessing artificial intelligence for prostate cancer management. August 8, 2024

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. August 8, 2024

A Phase 1b Dose Escalation Study of FOR46, a Novel Antibody-Drug Conjugate Targeting a Tumor-Specific Epitope of CD46, in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer August 7, 2024

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. August 7, 2024

Early Identification and Management of Patients with Rash on Apalutamide. August 7, 2024

From foes to friends: rethinking the role of lymph nodes in prostate cancer. August 7, 2024

Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. August 7, 2024

18F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology. August 7, 2024

Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT. August 7, 2024

Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy. August 7, 2024

Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study. August 7, 2024

Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients August 6, 2024

Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study. August 6, 2024

Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. August 6, 2024

PSA Levels and Mortality in Prostate Cancer Patients. August 6, 2024

Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer. August 6, 2024

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. August 6, 2024

Page 37 of 1449